J2787 HCPCS code: Riboflavin 5'-phosphate, ophthalmic solution (photrexa viscous/photrexa), up to 3 ml
J2787 is the HCPCS Level II code for riboflavin 5'-phosphate, ophthalmic solution (photrexa viscous/photrexa), up to 3 ml. In 2024 Medicare paid an average of $1,635.12 per service for J2787 across 146 services. Its Medicare coverage code is C (Carrier judgment): Coverage is decided by the Medicare contractor (MAC) case by case. The NCCI unit limit is 2 per day on outpatient hospital claims. Medicare volume rose 115% from 2022 to 2024 (68 to 146 services). In 2024, about 49 clinicians billed Medicare for J2787 for 62 beneficiaries.
Code details
| Field | Value |
|---|---|
| Section | J codes — Drugs administered other than oral method |
| Coverage code | C — Carrier judgment |
| Pricing indicator | 51 — Drug or biological (priced per ASP/average sales price rules) |
| BETOS category | O1E — Other drugs |
| Added | 2019-01-01 |
| Last action effective | 2026-07-01 |
Who bills J2787 (2024)
| Measure | Value |
|---|---|
| Clinicians billing (by place of service) | 49 |
| Medicare beneficiaries | 62 |
| States with claims | 0 |
Counts only. Supplier and clinician names, contact lists and state-by-state detail are in Caduvo.
Medicare utilization for J2787, 2022–2024
| Year | Services | Beneficiaries | Avg. allowed | Avg. paid |
|---|---|---|---|---|
| 2022 | 68 | 31 | $1,692.00 | $1,347.70 |
| 2023 | 74 | 33 | $1,464.75 | $1,168.52 |
| 2024 | 146 | 62 | $2,051.57 | $1,635.12 |
NCCI unit limits (MUE)
| Claim type | Max units per day | Rationale |
|---|---|---|
| outpatient hospital claims | 2 | Prescribing Information |
| practitioner claims | 2 | Prescribing Information |
What changed for J2787
- July 2026: Descriptor revised (Was: Riboflavin 5'-phosphate, ophthalmic solution, up to 3 ml)
- 2019-01-01: J2787 added to HCPCS Level II
- Next scheduled CMS quarterly update (HCPCS and DMEPOS fee schedule): 2027-01-01
Frequently asked questions
What is HCPCS code J2787?
J2787 is the HCPCS Level II code for riboflavin 5'-phosphate, ophthalmic solution (photrexa viscous/photrexa), up to 3 ml. Short descriptor: "Riboflavin photrexa/viscous".
How much does Medicare pay for J2787?
In 2024, the average Medicare payment was $1,635.12 per service (average allowed $2,051.57).
Does Medicare cover J2787?
Coverage code C — Carrier judgment. Coverage is decided by the Medicare contractor (MAC) case by case.
How many units of J2787 can be billed per day?
2 on outpatient hospital claims; 2 on practitioner claims (NCCI medically unlikely edits).
Related J27 codes
- J2700 — Injection, oxacillin sodium, up to 250 mg
- J2704 — Injection, propofol, 10 mg
- J2710 — Injection, neostigmine methylsulfate, up to 0.5 mg
- J2711 — Injection, neostigmine methylsulfate 0.1 mg and glycopyrrolate 0.02 mg
- J2720 — Injection, protamine sulfate, per 10 mg
- J2724 — Injection, protein c concentrate, intravenous, human, 10 iu
- J2725 — Injection, protirelin, per 250 mcg
- J2730 — Injection, pralidoxime chloride, up to 1 gm
- J2760 — Injection, phentolamine mesylate, up to 5 mg
- J2765 — Injection, metoclopramide hcl, up to 10 mg
- J2770 — Injection, quinupristin/dalfopristin, 500 mg (150/350)
- J2777 — Injection, faricimab-svoa, 0.1 mg
Building a device that would bill under a code like this? Caduvo matches a device description to HCPCS/CPT codes, Medicare coverage and payment, and the FDA pathway in one report.
Next steps
- Run a reimbursement report for a device billed under J2787
- Watch J2787 for fee, coverage and descriptor changes
- Build a full Medicare revenue model for J2787
Compiled by Caduvo from public CMS (Medicare) records, HCPCS release October 2026. Fees are Medicare allowables, not commercial rates. Not reviewed or endorsed by CMS. Not billing or legal advice. Report an error. Data and corrections policy.